Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...

Coherus Completes Divestiture of Ophthalmology Franchise – Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) --...

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal – Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus...

Sandoz Canada remains among Top Employers in Montreal and gains new Top Employer Canada certification for 2019 Boucherville, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sandoz Canada has been selected as one of Montreal’s Top Employers for a second year in a row and was also amongst Canada’s Top 100 Employers in...

Sandoz Canada receives Health Canada approval for Erelzi® (etanercept) in the Treatment of Psoriatic Arthritis (PsA) in Adult Patients Boucherville, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients.Up to...